About the Company
Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. Imago is focused on improving the quality and length of life for patients with cancer and bone marrow diseases. Bomedemstat, an orally available, small molecule inhibitor of LSD1, is the lead product candidate discovered by Imago for the treatment of certain myeloproliferative neoplasms (MPNs), a family of related, chronic cancers of the bone marrow. Imago is evaluating Bomedemstat as a potentially disease-modifying therapy in two Phase 2 clinical trials for the treatment of essential thrombocythemia (NCT04254978) and myelofibrosis (NCT03136185). Bomedemstat has U.S. FDA Orphan Drug and Fast Track Designation for the treatment of ET and MF, European Medicines Agency (EMA) Orphan Designation for the treatment of ET and MF, and PRIority MEdicines (PRIME) Designation by the EMA for the treatment of MF. The company is based in South San Francisco, California.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $IMGO News
Merck bulks up in haematology, buying Imago for $1.35bn
Merck & Co has continued to bolster its pipeline with smaller deals – with its latest a $1.35 billion agreement to buy Imago BioSciences and its bomedemstat drug candidate for blood disorders.
Merck to acquire Prometheus Biosciences for $10.8B
Merck recently made another deal, agreeing to acquire blood-cancer biotech Imago BioSciences for $1.35 billion. The Wall Street Journal first reported that talks were underway.
What 5 Analyst Ratings Have To Say About IGM Biosciences
In the last three months, 5 analysts have published ratings on IGM Biosciences (NASDAQ:IGMS), offering a diverse range of ...
LENSAR Stock (NASDAQ:LNSR), Quotes and News Summary
Gainers AgileThought, Inc. (NASDAQ: AGIL) rose 96.5% to $0.3046 in pre-market trading after falling 17% on Tuesday. Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at ...
Patrick J Heron's Net Worth
Who is Patrick J Heron? Patrick J Heron has an estimated net worth of $804 Million. This is based on reported shares across multiple companies, which include Vaxcyte, Inc., Trubion Pharmaceuticals ...
IGMS IGM Biosciences, Inc.
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops ...
Yield10 Bioscience, Inc. (YTEN)
Yield10 Bioscience, Inc. (NASDAQ:YTEN) Q4 2023 Earnings Call Transcript April 1, 2024 Yield10 Bioscience, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS, expectations were $-0.11.
Forte Biosciences Inc Ordinary Shares FBRX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Aura Biosciences Inc AURA
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
CTKB Cytek Biosciences, Inc.
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and ...
Forte Biosciences Inc.
Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. The firm's lead product includes FB-401, which is a live biotherapeutic ...
Loading the latest forecasts...